Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study (2019)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1016/j.jtho.2019.03.002
- Subjects: NEOPLASIAS PULMONARES; PROTEÍNAS QUINASES; JEJUM; ALIMENTOS; GASTROENTEROPATIAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of thoracic oncology
- ISSN: 1556-0864
- Volume/Número/Paginação/Ano: v. 14, n. 7, p. 1255-1265, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
CHO, Byoung Chul et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, v. 14, n. 7, p. 1255-1265, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.03.002. Acesso em: 28 dez. 2025. -
APA
Cho, B. C., Obermannova, R., Bearz, A., Mckeage, M., Kim, D. -W., Batra, U., et al. (2019). Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, 14( 7), 1255-1265. doi:10.1016/j.jtho.2019.03.002 -
NLM
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002 -
Vancouver
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
- Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)
- Epidemiologia do câncer de pulmão
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
Informações sobre o DOI: 10.1016/j.jtho.2019.03.002 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
